Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)
July 12, 2022 07:00 ET | Synlogic, Inc.
Expected data in H2 2022 brings Synlogic to three clinical readouts this year Third candidate in less than two years to enter the clinic; Reflects productivity of Synthetic Biotic platform ...
Travere Therapeutics Provides Corporate Update and 2022 Outlook
January 10, 2022 07:00 ET | Travere Therapeutics, Inc.
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...
Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
December 15, 2021 07:00 ET | Travere Therapeutics, Inc.
Treatment with highest dose pegtibatinase led to a clinically meaningful 55% mean reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment Results...
Travere Therapeutics Reports First Quarter 2021 Financial Results
May 06, 2021 16:01 ET | Travere Therapeutics, Inc.
Pivotal PROTECT Study of sparsentan in IgA nephropathy nears completion of patient enrollment; topline proteinuria data expected 3Q21 Net product sales of $47.4 million for the first quarter of...
Retrophin Logo.jpg
Retrophin Reports Third Quarter 2020 Financial Results
November 05, 2020 16:01 ET | Retrophin, Inc.
Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21 Pivotal PROTECT Study achieved enrollment of 280th patient with IgAN to enable...
Retrophin Logo.jpg
Retrophin Announces Agreement to Acquire Orphan Technologies
October 22, 2020 16:01 ET | Retrophin, Inc.
Agreement adds OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria Compelling strategic fit that will expand pipeline of potential...
Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
April 08, 2020 07:30 ET | Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions...